ClinicalTrials.gg
CompletedNCT04435392Updated Apr 2, 2024

Jaktinib Hydrochloride Cream For Atopic Dermatitis

A Phase 1/2 interventional study of Jaktinib Hydrochloride Cream and Placebo in Atopic Dermatitis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
127th of 190
107 · median 164
Started
2020
with 7 others
Phase 1/2
15 of 206
5 open now
Registered
21st of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 127th largest by enrollment of the 190 interventional ones that give a count, is one of 8 that started in 2020, is one of 15 in phase 1/2, and was the 21st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This study includes a dose escalation part and a dose extension part.

Read the detailed description

In the dose-increasing part, a multicenter, dose-increasing, randomized, double-blind, placebo-parallel control design was adopted. Subjects were enrolled into different dose groups in sequence according to the inclusion sequence, and each group was scheduled to give the drug for 8 weeks.Subjects in each group were observed for 4 weeks after administration. When the number of ≥2 grade drug-related adverse events (cases) was less than 50%, subjects in the next group could be enrolled.Otherwise, IDMC will decide whether to continue the next set of tests.Subjects in each group were randomly assigned to receive either Jaktinib cream (6 cases) or placebo (2 cases) in a ratio of 3 to 1.A total of 32 subjects are expected to be enrolled in 6 centers.

The dose expansion was a multicenter, randomized, double-blind, placebo-parallel control design in which subjects were randomly assigned to 3 groups (1 placebo group and 2 experimental drugs group).It is estimated that a total of 60 subjects will be enrolled in about 15 centers. This part is divided into two stages.Stage 2 test (9 \~ 16 weeks) : Extension test.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Jaktinib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18\~ 65 years old (including boundary value), gender is not limited;
  • Have a clinical diagnosis of atopic dermatitis;
  • Have a PGA(Physician's Global Assessment) score of 2 (mild) or 3 (moderate) at baseline;
  • The total area of atopic dermatitis is about 10%\~20% of the total area of the body surface at baseline.

Exclusion criteria

Exclusion Criteria:

  • Evidence of certain skin conditions/infections at baseline;
  • Have certain laboratory abnormalities at baseline;
  • Females who are pregnant, breastfeeding, or are of not using highly effective ;
  • Other conditions that the investigators considered inappropriate to participate in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1, 0.5% Jaktinib Bid

    Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 0.5% Cream will be applied topically twice daily.

    Drug: Jaktinib Hydrochloride Cream · Drug: Placebo

  • Experimental
    Part 1: Cohort 2,1.5% Jaktinib Bid

    Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 1.5% Cream will be applied topically twice daily.

    Drug: Jaktinib Hydrochloride Cream · Drug: Placebo

  • Experimental
    Part 1: Cohort 3, 2.5% Jaktinib Qd

    Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically Once daily.

    Drug: Jaktinib Hydrochloride Cream · Drug: Placebo

  • Experimental
    Part 1: Cohort 4, 2.5% Jaktinib Bid

    Subjects were randomly assigned to receive either Jaktinib cream or a placebo in a ratio of 3 to 1.The Jaktinib hydrochloride 2.5% Cream will be applied topically twice daily.

    Drug: Jaktinib Hydrochloride Cream · Drug: Placebo

  • Placebo comparator
    Dose extension: Vehicle Control

    the Vehicle Control cream will be applied topically twice daily

    Drug: Placebo

  • Experimental
    Dose extension: low-dose group, X%

    X% based on results of part 1. The Jaktinib Hydrochloride X% Cream will be applied topically twice daily

    Drug: Jaktinib Hydrochloride Cream

  • Experimental
    Dose extension: high-dose group, Y%

    Y% based on results of part 1. The Jaktinib Hydrochloride Y% Cream will be applied topically twice daily

    Drug: Jaktinib Hydrochloride Cream

Interventions

  • Subjects in each group were scheduled to give the drug for 8 weeks.

    Also known as: Jaktinib

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear

    A total PGA score of 0 or 1 or a decrease of ≥2 from baseline

    Time frame: 7 days after the last dose

Secondary outcomes

  1. Proportion of Participants With Response of Clear or Almost Clear From Baseline

    PGA score of 0 or 1

    Time frame: Treatment at 8,16 weeks

07

Study locations

1 site
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Sep 2022, 22 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 22 months is close to that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 17, 2020
StartActual
Oct 14, 2020
Primary completionActual
Sep 8, 2022
CompletionActual
Sep 8, 2022
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04435392
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Oct 14, 2020
Primary completion
Sep 8, 2022
Completion
Sep 8, 2022
Last update
Apr 2, 2024

Study contacts

Qianjin Lu, PhD
principal investigator · Central South University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion